NEW YORK (GenomeWeb News) — Tripos will not sell its Discovery Research business to Provid Pharmaceuticals, according to a Securities and Exchange Commission filing on Friday.
 
Tripos told Provid on April 2 that it has terminated the stock purchase agreement the companies signed in early January, under which Provid would have acquired Discovery Research for $2 million in cash.
 

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

CNN reports that researchers have tied a new variant to opioid addiction risk.

Organoids derived from patients' tumors may help determine what chemotherapy treatment patients would benefit from, according to New Scientist.

An initiative from GenomeAsia 100K hopes to increase the number of South Asians in genetic research, according to NBC News.

In Science this week: genomic analysis of ancient and modern horses indicates population turnover, and more.